Clinical Trial Update: The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial assessing whether 6% hydroxyethyl starch 130/0.4 influences blood loss and coagulation in patients on antiplatelet therapy undergoing off-pump cor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Hydroxyethyl starch 130/0.4 (hydroxyethyl starch 130/0.4)

Snippet

Sponsor: Yonsei University | Conditions: Coronary Artery Occlusive Disease | Phase 4 | Status: COMPLETED